Publications by authors named "Kerry Rogers"

Claim this Profile
C
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.
Andrea Visentin, Enrico Gaffo, Moritz Fürstenau, Kerry A Rogers, Baliakas Panagiotis

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert consensus opinion on the management of hairy cell leukemia in elderly patients.
Tamar Tadmor, Judit Demeter, Andrei Fagarasanu, Robert J Kreitman, Sameer A Parikh, Kerry A Rogers

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.
Kerry A Rogers, Pearlly Yan, Ian W Flinn, Deborah M Stephens, Thomas J Kipps

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation.
Aseel Alsouqi, Ying Huang, Beth Christian, John Reneau, Seema A Bhat, Kerry A Rogers

Eur J Haematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PKCβ inhibitor MS-553 displays preclinical efficacy in both treatment-naïve and BTK inhibitor-resistant Chronic Lymphocytic Leukemia.
Britten K Gordon, Elizabeth M Muhowski, Jyotsana Singh, Janani Ravikrishnan, Arnau Peris-Cuesta, Kerry A Rogers

Blood Cancer Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era.
Cecelia R Miller, Ying Huang, John N Allan, Seema A Bhat, David Bond, Kerry A Rogers

Am J Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms.
Vineeth Sukrithan, Uzair Ahmed, Harris Krause, Nishant Gandhi, Andrew Elliott, Kerry A Rogers

Endocr Relat Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study.
Eleonora Roncaglia, Enrico Gaffo, Giulia Calabretto, Moritz Fürstenau, Kerry A Rogers

J Hematol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.
Kerry A Rogers, Benyam Muluneh, Zaina P Qureshi, Jinghua He, Alex Bokun

J Comp Eff Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-V600E BRAF mutations and treatment for hairy cell leukemia.
Evgeny Arons, Chin-Hsien Tai, Joshi Suraj, Yuelin Liu, Chi-Ping Day, Kerry Rogers

Blood· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.
Adam S Kittai, Ying Huang, Sarah Miller, John N Allan, Seema A Bhat, Kerry A Rogers

Blood Cancer J· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Out-of-pocket expenses and hospital write-offs are associated with patient reported financial toxicity.
Katharine M Esselen, Annika Gompers, Rasha A Baig, Nadiha Noor Chelsea, Kerry Rogers

Support Care Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?
Kerry A Rogers, Jennifer A Woyach

Hematology Am Soc Hematol Educ Program· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choosing between CAR T-cell therapy and pirtobrutinib in double-refractory CLL.
Kerry A Rogers

Clin Adv Hematol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation.
John Alan Gambril, Sanam M Ghazi, Stephen Sansoterra, Mussammat Ferdousi, Onaopepo Kola-Kehinde, Kerry Rogers

Leukemia· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia.
Nilesh Kapoor, Qiuhong Zhao, Andrew Stiff, Seema A Bhat, Mirela I Anghelina, Kerry A Rogers

EJHaem· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation.
Nilanjan Ghosh, Ruibin Wang, Zaina P Qureshi, Zhijie Ding, Marie-Hélène Lafeuille, Kerry A Rogers

Blood Neoplasia· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hairy cell leukemia variant and WHO classification correspondence Re: 5 edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
Michael Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons, Versha Banerji, Kerry A Rogers

Leukemia· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
Adam S Kittai, David Bond, Ying Huang, Seema A Bhat, Emily Blyth, Kerry A Rogers

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia.
Kerry A Rogers

Lancet Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pairing obinutuzumab with venetoclax in relapsed CLL.
Kerry A Rogers, Philip A Thompson

Leuk Lymphoma· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Paul J Hampel, Mahesh Swaminathan, Kerry A Rogers, Erin M Parry, Jan A Burger

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Jennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, Cecelia Miller, Nyla A Heerema, Kerry A Rogers

Blood· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
Adam S Kittai, Ying Hang, Seema A Bhat, Abi Clark, Michael Grever, Kerry A Rogers

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.
Matthew R Avenarius, Ying Huang, Adam S Kittai, Seema A Bhat, Kerry A Rogers

Leukemia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis